title: Vemurafenib (ZELBORAF®tablet 240 mg): pharmacological properties and clinical development overview.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Shimada
authors.forename: Kyoko
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Aoki
authors.forename: Atsuko
authors.initials: A
authors.lastname: Kajihara
authors.forename: Takahiro
authors.initials: T
authors.lastname: Mizui
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D013449:Sulfonamides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D013607:Tablets; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D013607:Tablets; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf